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OBJECTIVE — To evaluate efﬁcacy and safety of switching from twice-daily exenatide to
once-daily liraglutide or of 40 weeks of continuous liraglutide therapy.
RESEARCH DESIGN AND METHODS — When added to oral antidiabetes drugs in a
26-weekrandomizedtrial(LiraglutideEffectandActioninDiabetes[LEAD]-6),liraglutidemore
effectively improved A1C, fasting plasma glucose, and the homeostasis model of -cell function
(HOMA-B) than exenatide, with less persistent nausea and hypoglycemia. In this 14-week
extension of LEAD-6, patients switched from 10 g twice-daily exenatide to 1.8 mg once-daily
liraglutide or continued liraglutide.
RESULTS — Switching from exenatide to liraglutide further and signiﬁcantly reduced A1C
(0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure
(3.8 mmHg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%).
Among patients continuing liraglutide, further signiﬁcant decreases in body weight (0.4 kg) and
systolic blood pressure (2.2 mmHg) occurred with 0.74 episodes/patient-year of minor hypo-
glycemia and 1.5% experiencing nausea.
CONCLUSIONS — Conversion from exenatide to liraglutide is well tolerated and provides
additional glycemic control and cardiometabolic beneﬁts.
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G
lucagon-like peptide (GLP)-1 re-
ceptor agonists improve glycemic
control and reduce weight with
minimal risk of hypoglycemia (1,2). The
ﬁrst randomized head-to-head compari-
sonoftwoGLP-1receptoragonistsadded
tooralantidiabetesagents(LiraglutideEf-
fect and Action in Diabetes [LEAD]-6)
showedthat1.8mgonce-dailyliraglutide
provided greater improvements in A1C
and fasting plasma glucose (FPG) with
lower hypoglycemia and less persistent
nausea than 10 g twice-daily exenatide
after 26 weeks; similar decreases in
weight (3 kg) and systolic blood pres-
sure (SBP) (2.0–2.5 mmHg) occurred
withbothdrugs(3).Theobjectivesofthis
14-week extension were to assess the
safety and efﬁcacy of switching from ex-
enatide to liraglutide, or continuing lira-
glutide for up to 40 weeks.
RESEARCH DESIGN AND
METHODS— TheLEAD-6designhas
been reported (3). Adults with type 2 di-
abetes inadequately controlled (A1C
7–11%) with maximally tolerated stable
doses of metformin, sulfonylurea, or both
for 3 months were randomized (1:1) to
1.8 mg liraglutide once daily or 10 g
exenatide twice daily. After 26 weeks, pa-
tients continued into a nonrandomized
14-week extension: all exenatide patients
were switched to 0.6 mg liraglutide once
daily for 1 week, then escalated to 1.2 mg
for another week, and then given a ﬁnal
maintenance dose of 1.8 mg. Patients
originally randomized to 1.8 mg lira-
glutide continued. Background oral an-
tidiabetes drugs remained unchanged,
although sulfonylurea doses could be de-
creased by 50% if unacceptable hypogly-
cemia occurred.
Visits occurred at weeks 2 (screen-
ing), 0 (randomization), 4, 8, 12, 20, 26,
34, and 40 for both groups. Efﬁcacy and
safety assessments during the extension
phase (weeks 26–40) were identical to
those previously described (3). Extension
intention-to-treat (ITT) (all randomized
patients exposed to trial product who en-
tered the extension) and extension safety
(all patients exposed to trial product who
entered the extension) populations were
used for efﬁcacy and safety analyses, re-
spectively. Changes from baseline (last
available observation up to 26 weeks) to
week 40 within each treatment group
wereanalyzedbypairedttests.Treatment
groups were not compared. Post-baseline
missing values were imputed using last
observation carried forward. Unless
noted, mean (SE) values are presented.
Signiﬁcance was P  0.05.
RESULTS— All 389 patients complet-
ing26weeksenteredtheextension.Three
patients who were not formally random-
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ITT population. Demographics were well
matched between groups and similar to
those previously reported (3). Overall,
376 of 389 patients (97%) completed the
extension: 10 of 187 (5.3%) with
exenatide liraglutide and 3 of 202
(1.5%) continuing liraglutide withdrew.
Withdrawals (n [%]) in the exena-
tide liraglutide and liraglutide groups,
respectively, were due to either adverse
events (6 [3.2%] and 0), ineffective ther-
apy (0 and 2 [1.0%]), protocol noncom-
pliance (0 and 1 [0.5%]), meeting
withdrawal criteria (1 [0.5%] and 0), or
other reasons (3 [1.6%] and 0). Demo-
graphic and screening characteristics
were similar between patients who with-
drew during the extension and those who
completed the extension, with the excep-
tion of mean duration of diabetes, which
Figure 1—Effect of switching from exenatide to liraglutide or continuing liraglutide on various measures of efﬁcacy (extension ITT population). A:
A1C over time. B: Percentage of patients reaching A1C targets at week 26 (after the main part of the trial) and week 40 (after the exenatide group
switched to liraglutide for 14 weeks). C: FPG over time. D: Body weight over time. E: SBP over time. All patients originally in the exenatide group
switched to liraglutide at week 26, whereas the liraglutide group continued liraglutide. Maroon represents liraglutide and blue exenatide. In B, the
whitelinewithineachbarindicatesthepercentageofpatientsreachingA1Ctargetsatweek26andthetopofthebarindicatesthepercentagereaching
A1Ctargetsatweek40.InAandC–E,dottedmaroonlinesindicatepatientswhoswitchedfromexenatidetoliraglutideatweek26.Valuesaremean
(2 SE). Post-baseline timepoints were imputed using last observation carried forward.
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years) than completers (7.9 years).
Efﬁcacy
MeanA1Cfurtherdecreasedfrom7.2%at
week 26 to 6.9% at week 40 (0.32 
0.043%; P  0.0001) after switching
from exenatide to liraglutide, but re-
mainedsimilarwithcontinuedliraglutide
(7.0 to 6.9%; 0.06  0.041%, P 
0.1222) (Fig. 1A). Additional patients
reached A1C targets after switching from
exenatide to liraglutide (Fig. 1B).
After switching from exenatide to li-
raglutide, further reductions in FPG (Fig.
1C; 0.9  0.16 mmol/l, P  0.0001),
body weight (Fig. 1D; 0.9  0.15 kg,
P  0.0001), and SBP (Fig. 1E; 3.8 
0.84mmHg,P0.0001)occurredwhile
the homeostasis model of -cell func-
tion (HOMA-B) assessment increased
(14.5  4.4%, P  0.001), consistent
with the FPG reductions. In patients
continuing liraglutide, reductions in
FPG(Fig.1C; 0.2 0.11mmol/l,P 
0.0973), body weight (Fig. 1D, 0.4 
0.15 kg, P  0.0089), and SBP (Fig. 1E;
2.2  0.88 mmHg, P  0.0128) oc-
curred. No signiﬁcant changes in post-
prandial glucose (except after lunch
with exenatide liraglutide [0.64 
0.21mmol/l,P0.0032],diastolicblood
pressure, fasting insulin, fasting C-
peptide, proinsulin-to-insulin ratio, or
homeostasis model assessment–insulin
resistance[HOMA-IR])occurredineither
group.
Safety
Similar numbers of patients reported one
or more adverse events during the exten-
sion (exenatide liraglutide: 70 [37.4%]
and liraglutide: 76 [37.6%]). Most ad-
verse events were mild in severity
(exenatide liraglutide: 79/117 events,
liraglutide: 81/120 events); investigators
assessed most as unrelated to trial drug
(exenatide liraglutide: 72/117 events,
liraglutide: 94/120 events).
Nausea and diarrhea occurred in
3.2% of patients switching from
exenatide liraglutide and 1.5% in
those continuing liraglutide, whereas
vomiting occurred in 0.5% switching
from exenatide liraglutide and 2.0%
in those continuing liraglutide.
One major hypoglycemic episode
occurred in a patient continuing lira-
glutide,whileextensionrates(episodes/
patient-year) of minor hypoglycemia
were 1.30 (exenatide liraglutide),
down from 2.60 with exenatide at week
26 (3), and 0.74 (liraglutide). Thirteen
adverse events associated with with-
drawal from the extension of six pa-
tients in the exenatide liraglutide
group were myocardial infarction, diar-
rhea(threeevents),impairedgastricemp-
tying, eructation, nausea, lethargy,
paraesthesia, anxiety, depressed mood,
depression,anddyspnea.Fortwoofthese
six patients, the adverse events associated
with their withdrawal from the extension
(nausea and diarrhea) had been previ-
ously reported as separate events during
the 26-week exenatide treatment period.
Four patients in the exena-
tide liraglutide group had seven severe
adverse events (cardiac failure, myocar-
dial infarction, cataract, chest discomfort,
chronic obstructive pulmonary disease
[twoevents],dyspnea).Fivepatientscon-
tinuing liraglutide had eight severe ad-
verse events (cerebral infarction,
cerebrovascular accident, transient isch-
emic attack, acute coronary syndrome, coro-
nary artery occlusion, portal vein thrombosis,
rectalcancer,anddepression).Twodeathsoc-
curred(exenatide liraglutide:myocardial
infarction after 198 days of treatment; li-
raglutide: cerebral infarction [patient
completed the study but died shortly af-
ter]). Investigators assessed all events as
“unlikely” to be related to trial product.
Calcitonin levels remained at the
lower level of the normal range (1 pg/
ml)anddidnotdifferbetweengroups.No
medullary thyroid carcinoma or pancre-
atitis cases were reported during the
extension.
CONCLUSIONS— This extension
shows that patients can be simply and
safely switched from twice-daily premeal
exenatide to meal-independent once-
daily liraglutide using weekly dose esca-
lation from 0.6 to 1.2 to 1.8 mg.
Conversion to liraglutide from exenatide
was well tolerated and further improved
glycemic control. Additional reductions
in body weight and SBP occurred in both
groups. Over 40 weeks, liraglutide re-
duced A1C by 1.3%.
The magnitude of these changes and
differences between liraglutide and ex-
enatide are consistent with results re-
ported in phase 3 LEAD (liraglutide)
(3–8) and exenatide (9–11) trials. The
greater efﬁcacy of liraglutide may be due
to sustained levels achieved over 24 h by
once-daily dosing compared with bipha-
sic levels achieved during the 2.4-h half-
life of exenatide after dosing within1ho f
breakfast and dinner (12).
Further studies are required to inves-
tigate the durability of these responses.
Given the likely preference for once-daily
meal-independent dosing, liraglutide ap-
pears to be a useful addition to the diabe-
tes treatment armamentarium.
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